Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 9/20 | 0.54 |
| ▸ | PIP4K2B | P78356 | 9/20 | 0.54 |
| ▸ | EGFR | P00533 | 9/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.46 |
| ▸ | ITK | Q08881 | 3/20 | 0.45 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.40 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13541428 | 0.99 | PIP4K2A (0.55) | PIP4K2APIP4K2BEGFRERBB2ITK | |
| SCHEMBL16158633 | 0.92 | PIP4K2A (0.46) | PIP4K2APIP4K2BEGFRERBB2ITK | |
| SCHEMBL13542732 | 0.90 | PIP4K2A (0.51) | PIP4K2APIP4K2BEGFRERBB2ITK | |
| SCHEMBL14213727 | 0.89 | PIP4K2A (0.51) | PIP4K2APIP4K2BEGFRERBB2ITK | |
| SCHEMBL14213728 | 0.88 | PIP4K2A (0.48) | PIP4K2APIP4K2BEGFRERBB2 | |
| SCHEMBL13541425 | 0.88 | PIP4K2A (0.52) | PIP4K2APIP4K2BEGFRERBB2ITK | |
| SCHEMBL13541429 | 0.88 | PIP4K2A (0.49) | PIP4K2APIP4K2BEGFRERBB2 | |
| SCHEMBL14773120 | 0.86 | PIP4K2A (0.48) | PIP4K2APIP4K2BEGFRERBB2ITK | |
| SCHEMBL13542769 | 0.84 | PIP4K2A (0.46) | PIP4K2APIP4K2BEGFRERBB2PIP4K2C | |
| SCHEMBL13542731 | 0.84 | EGFR (0.47) | PIP4K2APIP4K2BEGFRERBB2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-8748606-B2 | 4,6-diaminopyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8329901-B2 | 4,6-disubstitued pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065892-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PIP4K2A 3115/4885PIP4K2B 2793/4885EGFR 1981/4885 |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PIP4K2A 3115/4885PIP4K2B 2793/4885EGFR 1981/4885 |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | PIP4K2A 3115/4885PIP4K2B 2793/4885EGFR 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.